JSR Life Sciences has acquired Selexis SA, a provider of mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create a streamlined “Gene to GMP” service offering for the biopharmaceutical industry. “Selexis has the best-in-class cell-...